Daniel Sharp
Follow
Get notifications in MyBN when activity occurs.
Upgrade your subscription to use this feature.
Daniel Sharp
Non-Executive Director / Botanix Pharmaceuticals
Daniel Sharp is an investment banker with over 30 years of senior executive experience within the investment banking and corporate finance sectors. He has been advising the boards of technology and healthcare-based organisations, and has a significant network of institutional and private wealth investors globally.
Mr Sharp started his career as a lawyer. He has managed IPOs, capital raisings and corporate advisory activities for many successful ASX-listed companies in the healthcare, technologies and general industrials sectors. He is also closely connected to strong networks of institutional, family office and high net-worth investors in Australia and overseas.
From 2012-2020, Mr Sharp was an executive director of corporate finance at Canaccord Genuity where he led dozens of equity capital market transactions and corporate finance advisory projects across the healthcare, life sciences, technologies, financial services and general industrials sectors. Prior to that, he headed the corporate finance division at two of Australia’s leading independent investment banking and stockbroking firms.
Mr Sharp started his career as a lawyer. He has managed IPOs, capital raisings and corporate advisory activities for many successful ASX-listed companies in the healthcare, technologies and general industrials sectors. He is also closely connected to strong networks of institutional, family office and high net-worth investors in Australia and overseas.
From 2012-2020, Mr Sharp was an executive director of corporate finance at Canaccord Genuity where he led dozens of equity capital market transactions and corporate finance advisory projects across the healthcare, life sciences, technologies, financial services and general industrials sectors. Prior to that, he headed the corporate finance division at two of Australia’s leading independent investment banking and stockbroking firms.
Lists and Charts
Total Shareholder Return as at 29/02/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 817th | Argo Global Listed Infrastructure | -6% | 5% |
| 1248th | Lark Distilling Co | -35% | 90% |
| 1652nd | Alcidion Group | -63% | 5% |
1790 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Roles
Year started and most recent title
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 594th |  | Alcidion Group | $40.4m |
| 688th | | Argo Global Listed Infrastructure | $20.4m |
| 689th | | Lark Distilling Co | $20.3m |
| 691st | | Proptech Group | $20.2m |
| 692nd | | MNC Media Investment | $20.1m |
1330 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Person Activity
| NEW ROLE: Non-Executive Director, Botanix Pharmaceuticals | 22 Mar 2022 |
| NEW ROLE: Non-Executive Director, Alcidion Group | 06 Sep 2021 |
